SPAC merger called off as company connected to ex-Purdue CEO decides to remain private

Paul Schloesser

Associate Editor

Sometimes, the third time is not the charm.

Blade Therapeutics announced Monday morning that the company and its proposed merger partner, Biotech Acquisition Company, mutually agreed to call things off, effective immediately. This takes place just seven months after Blade, the small San Francisco biotech where ex-Purdue CEO Mark Timney is board chair, announced the reverse merger worth $254.3 million.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

SPAC merger called off as company connected to ex-Purdue CEO decides to remain private

Paul Schloesser

Associate Editor

Unlock this article instantly by becoming a free subscriber.

Principal

Alexandria Real Estate Equities

Cambridge, MA, USA

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

FDA unveils new rare disease pilot program to increase agency-sponsor communications

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

Data Quality 2.0: The Future of Real-World Evidence

SPAC merg­er called off as com­pa­ny con­nect­ed to ex-Pur­due CEO de­cides to re­main pri­vate

Associate Editor

Unlock this article instantly by becoming a free subscriber.

Alexandria Real Estate Equities

Cambridge, MA, USA

SPAC merger called off as company connected to ex-Purdue CEO decides to remain private